Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum
Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum
复制标题
DOI：
10.1097/iae.0b013e31809ff5df
复制
发表时间：
2007-09-01
影响因子：
3.3
通讯作者：
Yannuzzi, Lawrence A.
中科院分区：
文献类型：
--
作者：
Bhatnagar, Pawan;Freund, K. Bailey;Yannuzzi, Lawrence A.
目的：为了确定玻璃体内贝伐单抗注射的结果与弹性假黄瘤（PXE）相关的血管样stries.Methods的脉络膜新生血管（CNV）的患者的管理：一个连续的系列与PXE和CNV的患者进行了管理与玻璃体内贝伐单抗注射（1.25毫克每0.05毫升）。主要结果的措施是视力和最大的病变高度测量的光学相干断层扫描（OCT）。结果：9眼的9个连续患者接受玻璃体内贝伐单抗（1.25 mg/0.05 mL）注射。平均随访时间为6个月，在此期间眼睛平均接受1.8次注射。基线视力平均为20/368，末次访视时改善至20/289（P = 0.056）。9眼（100%）视力均提高或稳定。8只眼睛的连续OCT测量结果显示，基线时平均值为353 Am，末次访视时降至201 Am（P = 0.012）。结论：这些短期结果支持使用玻璃体内贝伐单抗治疗PXE患者的CNV。玻璃体内贝伐珠单抗在这一人群中的持续经验将有助于建立其长期疗效，并更好地确定连续注射以维持这些结果的潜在需求。
Purpose: To determine the results of intravitreal bevacizumab injections for the management of choroidal neovascularization (CNV) in patients with pseudoxanthoma elasticum (PXE)-associated angioid streaks.Methods: A consecutive series of patients with PXE and CNV were managed with intravitreal bevacizumab injection (1.25 mg per 0.05 cc). The main outcome measures were visual acuity and greatest lesion height as measured by optical coherence tomography (OCT).Results: Nine eyes of nine consecutive patients received intravitreal bevacizumab (1.25 mg/0.05 mL) injections. The mean follow-up time was 6 months, during which eyes received an average of 1.8 injections. The baseline visual acuity was a mean of 20/368 and improved to 20/289 at the last visit (P = 0.056). Visual acuity either improved or stabilized in all 9 eyes (100%). Serial OCT measurements in 8 eyes showed a mean of 353 Am at baseline, which decreased to 201 Am at the last visit (P = 0.012). No complications were noted.Conclusions: These short-term results support the use of intravitreal bevacizumab for the management of CNV in patients with PXE. Continued experience with intravitreal bevacizumab in this population will help establish its longer-term efficacy and better define the potential need for serial injections to maintain these results.